Pre-market hot trades in US stocks: Opendoor Tech Series Z - CW26 up 7.14% in pre-market; Texas Instruments down 3.05% in pre-market

Popular Pre-Market Trades in U.S. Stocks Opendoor Tech Series Z - CW26, up 7.14% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. Texas Instruments down 3.05% in pre-market trading. Based on recent key news: On December 14, Texas Instruments reached a strategic cooperation with UBTECH to procure the industrial humanoid robot Walker S2 and deploy applications. This move aims to promote automation in the semiconductor manufacturing industry; however, the market is cautious about its short-term profitability, leading to a decline in stock price. On December 15, Texas Instruments' robotic collaboration sparked ethical controversies regarding autonomous weaponization, with public concerns about the combination of robotic dogs and guns affecting market confidence and further depressing stock prices. On December 12, Mairs & Power Investment Advisors released a report indicating that the market is concentrated on a few AI giants, and Texas Instruments has not significantly benefited from this trend, leading investors to be cautious about its future growth. The semiconductor industry faces competitive pressure, and policy changes need to be monitored. Top Gainers in U.S. Pre-Market Trading Radiopharm Theranostics up 234.04% in pre-market trading. Based on recent key news: On December 15, Radiopharm Theranostics announced that its RAD 101 Phase 2B imaging trial achieved 92% of its primary endpoint in patients with brain metastases. This positive mid-term analysis significantly boosted market confidence in the company's future development, driving a substantial increase in stock price. The biotechnology sector has been active recently, attracting high investor attention. 3 E Network Tech, up 86.86% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. Milestone Pharmaceuticals up 38.17% in pre-market trading. Based on recent key news: On December 12, Milestone Pharmaceuticals announced that its first commercial product, CARDAMYST™ nasal spray, received approval from the U.S. FDA. This medication is used for the treatment of paroxysmal supraventricular tachycardia (PSVT), providing patients with a rapid self-management treatment option. This news significantly boosted the company's stock price. On December 13, Milestone Pharmaceuticals announced that CARDAMYST™ is expected to enter retail pharmacies in the first quarter of 2026. Strong clinical data and financial support lay the foundation for the product's commercialization, further enhancing market confidence On December 15th, the company plans to hold a conference call and live webcast to further discuss the market prospects and commercialization strategies of its products. This series of positive news has attracted strong attention from investors, driving up the stock price. The approval of innovative products in the pharmaceutical industry has received a positive market response